

Clinical Diversity Impacts Patients

Gilliosa SPURRIER-BERNARD MPNE & MelanomeFrance

CDDF ANNUAL CONFERENCE Challenges in clinical trial performance

6 - 8 February 2023



Disclaimer

MPNE is a volunteer based network some of whose activities are funded by balanced support from project and support funding from : Amgen, BMS, Merck MSD, Novartis and Roche. Support never includes editorial rights or influence on MPNE's program or activities.

Gilliosa SPURRIER-BERNARD has received honoraria from MSD, Servier, BMS.

CDDF ANNUAL CONFERENCE



Diversity Gaps in Melanoma

- The BRAF gap is still causing access issues 10 years on
- Brain Mets kill the most people and yet they are almost always excluded
- Mucosal, Acral and Uveal Melanoma exclusions cost lives and miss opportunities
- QOL Tools need to pick up diversity toxicity disparities, dosage, etc.
- Diverse Clinical Trials sites will pick up different populations

CDDF ANNUAL CONFERENCE Challenges in clinical trial performance

6 - 8 February 2023



CDDF

ANNUAL CONFERENCE

Making a start on Solutions

Fig. 1: Socioecological framework to increase diversity in clinical research.

From: Improving diversity in medical research

 Public policy Set global standards for diversity in clinical trials Adopt international guidelines requiring representation of diverse populations for regulatory approvals Enact continuous post- marketing surveillance to monitor effectiveness in 	 Community Involve patients and communities in the development of study questions Ensure the intended population can be reached with the planned study recruitment methods 	 Institutional Develop knowledge resources specific to communities with historical medical mistrust Provide data for drug efficacy across different papulations 	 Interpersonal Ensure diversity in research and development teams Plan and track inclusion of diverse populations through- out the discovery cycle Collect sociodemographic data of study populations in trials using uniform data standards 	 Intrapersonal Understand individual knowledge, beliefs and attitudes towards clinical research Provide support to encourage research participation, such as transportation and financial assistance
monitor effectiveness in diverse populations	planned study recruitment methods	across different populations	using uniform data standards	financial assistance

Changes to public policy, community, institutional, interpersonal and intrapersonal domains can result in increased diversity in research and help overcome inequalities in health care and patient outcomes.

Ref: Sharma et al Nature Reviews 2021

Challenges in clinical trial performance 6 - 8 February 2023



Conclusions

- Recognize the domains of diversity and their relevance in different settings
- Assess how much a Clinical Trial differs from Reality coefficients?
- Penalize those that don't match the Real Patient Population
- Be accommodating in the Trial design to allow access to patient populations that need the trial as treatment option
- Reduce the efficacy and effectiveness gap by coordinating RWE and CTs by matching criteria and relevant endpoints

• Truly fair Precision Medicine Trials for those out of options can CDDF be diverse if supported everywhere ANNUAL CONFERENCE 6 - 8 February 2023



Thankyou for Listening

gilliosa.spurrier-bernard@mpneurope.org gilliosa@melanomefrance.com

https://www.mpneurope.org





Challenges in clinical trial performance 6 - 8 February 2023

CDDF ANNUAL CONFERENCE